Pomerantz LLP investigates AstraZeneca over failed trial and stock drop.

Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary endpoint, causing AstraZeneca's stock to drop 5.7% on July 9, 2026. The investigation aims to determine if AstraZeneca engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for potential class action participation.